Diagnostic Tests

CLINICAL ASSOCIATIONS

With conventional anti-citrullinated protein autoantibody (ACPA) or anti-cyclic citrullinated peptide (CCP) testing missing approximately 10-15% of patients suffering from rheumatoid arthritis, Mitogen’s Arthritis Panel is a comprehensive rheumatoid arthritis test that addresses missed diagnoses. By adding novel autoantibody targets, Mitogen’s Arthritis panel achieves significant improvements in sensitivity for diagnosing rheumatoid arthritis over conventional ACPA testing.

With the availability of this test, clinicians should avoid the costs and loss-of-time that inherent with early generations of CCP testing. By solely ordering this panel for suspected RA and known RA patients you gain an increased chance in early detection and missing fewer diagnostic opportunities.